Cascade Microtech Reports Fourth Quarter and Annual 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cascade Microtech Reports Fourth Quarter and Annual 2015 Results

BEAVERTON, OR--(Marketwired - Feb 4, 2016) - Cascade Microtech, Inc. ( NASDAQ : CSCD )

  • Record Annual Revenue of $144.0 million
  • Record Quarterly Revenue of $40.4 million
  • Record Annual Income from Operations of $17.9 million
  • Record Quarterly Income from Operations of $6.5 million
  • Record Quarterly Bookings of $48.7 million

Cascade Microtech, Inc. ( NASDAQ : CSCD ) today reported financial results for the fourth quarter and year ended December 31, 2015.

Cascade Microtech also announced today that it has entered into a merger agreement with FormFactor, Inc. ( NASDAQ : FORM ) ("FormFactor") pursuant to which FormFactor has agreed to acquire Cascade Microtech. The Company has provided details of the merger in a separate press release.

Financial Summary

Results for the quarter ended December 31, 2015 were as follows:

  • Total revenue of $40.4 million, compared to $35.8 million for Q3 2015 and $36.6 million for Q4 2014. 
    • Systems revenue of $21.7 million, an increase of $2.5 million, or 13.3%, over Q3 2015, and an increase of $0.3 million, or 1.5%, from Q4 2014. 
    • Probes revenue of $18.7 million, an increase of $2.1 million, or 12.5%, over Q3 2015, and an increase of $3.5 million, or 22.9%, over Q4 2014.
    • Q4 2015 represents record revenue overall and for our Probes segment. 
  • Gross margin of 56.3%, down from 56.7% in Q3 2015 and up from 53.4% in Q4 2014. 
    • Systems gross margin of 49.8%, down from 50.3% in Q3 2015 and up from 48.1% in Q4 2014.
    • Probes gross margin of 63.9%, consistent with 63.9% in Q3 2015 and up from 60.8% in Q4 2014.
  • Income from operations of $6.5 million, an increase of $2.0 million, or 44.9%, over Q3 2015, and an increase of $2.4 million, or 58.0%, over Q4 2014.
    • Q4 2015 sets a new record for income from operations. 
  • GAAP net income of $4.2 million, or $0.25 per diluted share, compared to $3.2 million, or $0.19 per diluted share, for Q3 2015, and $4.3 million, or $0.25 per diluted share, for Q4 2014.
    • Q4 2015 includes income tax expense of $2.1 million, compared to an expense of $1.3 million for Q3 2015, and a benefit of $0.4 million for Q4 2014. 
  • Non-GAAP net income of $4.5 million, or $0.28 per diluted share, compared to $3.4 million, or $0.20 per diluted share, for Q3 2015, and $4.4 million, or $0.26 per diluted share, for Q4 2014. 
    • Q4 2015 sets a new record for non-GAAP earnings per share.
  • Depreciation, amortization and stock-based compensation expenses totaled $2.3 million, compared to $2.2 million for Q3 2015, and $2.1 million for Q4 2014. 
  • Adjusted EBITDAS of $8.8 million, compared to $6.7 million for Q3 2015, and $7.5 million for Q3 2015.
    • Q4 2015 sets a new record for adjusted EBITDAS.
  • Book-to-bill ratio of 1.21 to 1.

Results for the year ended December 31, 2015 were as follows:

  • Total revenue of $144.0 million, compared to $136.0 million for 2014. 
    • Systems revenue of $77.9 million, a decrease of $5.0 million, or 6.0%, from 2014. 
    • Probes revenue of $66.1 million, an increase of $13.0 million, or 24.4%, over 2014.
    • 2015 represents record revenue overall and for our Probes segment.
  • Gross margin of 55.6%, up from 51.7% in 2014.
    • 2015 sets a new record for gross margin.
  • Income from operations of $17.9 million, an increase of $4.6 million, or 34.7%, over 2014.
    • 2015 sets a new record for income from operations.
  • GAAP net income of $12.4 million, or $0.73 per diluted share, compared to $9.9 million, or $0.59 per diluted share, for 2014. 
    • 2015 includes income tax expense of $5.5 million, compared to an expense of $2.7 million for 2014. 
  • Non-GAAP net income of $13.8 million, or $0.81 per diluted share, compared to $11.2 million, or $0.67 per diluted share, for 2014.
  • Depreciation, amortization and stock-based compensation expenses of $8.4 million, compared to $8.8 million for 2014. 
  • Adjusted EBITDAS of $26.5 million, compared to $22.8 million for 2014.
  • Annual book-to-bill ratio of 1.04 to 1.

"Cascade Microtech set quarterly records for production probe and analytical probe card revenue, overall revenue, income from operations, adjusted EBITDAS, and bookings. As a percentage of revenue, in the fourth quarter we improved our adjusted EBITDAS to 21.8% which compares favorably to our stated success model target of 22%. This achievement reflects our customers growing demand for Cascade products and services as well as the leverage of our financial model. This financial performance was achieved as we increased our investments in R&D for new product development," said Michael Burger, President and CEO. "On an annual basis, records were set for probes segment revenue, overall revenue, gross margins, income from operations, adjusted EBITDAS and non-GAAP EPS. With a very strong close to 2015 together with record backlog, we expect to financially outperform our 2015 results and grow faster than the markets we serve in 2016."

Financial Outlook

For the first quarter of 2016 we are projecting revenue in the range of $33.0 million to $37.0 million, with diluted GAAP earnings per share in the range of $0.08 to $0.14, and non-GAAP earnings per share in the range of $0.10 to $0.16. Our guidance assumes a tax rate of 32%, consistent foreign currency exchange rates and no significant one-time charges.

The companies will hold a joint conference call today at 8:30 a.m. Eastern (5:30 a.m. Pacific) to discuss this announcement. The conference call can be joined by dialing 877-331-4217 , Conference ID 42589273, within the U.S. and 224-633-1404 , Conference ID 42589273, for all other locations. To access the webcast, visit the Investors section of Cascade Microtech's web site at  www.cascademicrotech.com /investors  to view the details. A webcast replay will be available on the Cascade Microtech web site approximately three hours after the conference call concludes.

   
CASCADE MICROTECH, INC.  
AND SUBSIDIARIES  
           
Condensed Consolidated Statements of Operations  
(in thousands, except per share data)  
(unaudited)  
                       
                       
    Three Months Ended          
    December 31,   September 30,   December 31,   Year Ended December 31,  
    2015   2015   2014   2015   2014  
                       
Revenue   $ 40,411   $ 35,781   $ 36,593   $ 143,978   $ 136,022  
Cost of sales     17,640     15,511     17,058     63,892     65,708  
Gross profit     22,771     20,270     19,535     80,086     70,314  
      56.3 %   56.7 %   53.4 %   55.6 %   51.7 %
Operating expenses:                                
  Research and development     4,757     4,344     3,598     16,965     13,821  
  Selling, general and administrative     11,474     11,414     11,797     45,230     43,209  
      16,231     15,758     15,395     62,195     57,030  
                                 
Income from operations     6,540     4,512     4,140     17,891     13,284  
                                 
Other income (expense):                                
  Interest income, net     7     14     4     15     29  
  Other, net     (293 )   (19 )   (289 )   (16 )   (649 )
      (286 )   (5 )   (285 )   (1 )   (620 )
                                 
Income before income taxes     6,254     4,507     3,855     17,890     12,664  
                                 
Income tax expense     2,093     1,288     (448 )   5,540     2,734  
                                 
Net income   $ 4,161   $ 3,219   $ 4,303   $ 12,350   $ 9,930  
                                 
Net income per share:                                
  Basic   $ 0.26   $ 0.19   $ 0.26   $ 0.75   $ 0.61  
  Diluted   $ 0.25   $ 0.19   $ 0.25   $ 0.73   $ 0.59  
                                 
Shares used in computing net income per share:                                
  Basic     15,933     16,529     16,435     16,396     16,323  
  Diluted     16,517     17,112     16,955     16,957     16,828  
                                 
                                 
 
CASCADE MICROTECH, INC. 
AND SUBSIDIARIES 
 
Condensed Consolidated Balance Sheets 
(in thousands) 
     (unaudited)      
 
             
    December 31,     December 31,  
Assets   2015     2014  
             
Current assets:                
  Cash and cash equivalents   $ 32,107     $ 38,107  
  Marketable securities     3,658       1,626  
  Restricted cash     10       61  
  Accounts receivable, net     27,716       20,763  
  Inventories     23,229       24,642  
  Prepaid expenses and other     6,597       4,454  
    Total current assets     93,317       89,653  
                 
Fixed assets, net     12,256       8,100  
Goodwill     11,592       12,823  
Purchased intangible assets, net     9,143       12,572  
Deferred income taxes     5,326       6,884  
Other assets     677       944  
                 
    $ 132,311     $ 130,976  
                 
                 
Liabilities and Stockholders' Equity                
                 
Current liabilities:                
  Accounts payable     8,834       7,505  
  Deferred revenue     1,617       2,070  
  Accrued liabilities     8,488       9,505  
    Total current liabilities     18,939       19,080  
                 
Deferred revenue     555       329  
Deferred income taxes     1,840       2,595  
Other long-term liabilities     1,581       1,511  
                 
    Total liabilities     22,915       23,515  
                 
Stockholders' equity:                
  Common stock     103,354       111,645  
  Accumulated other comprehensive loss     (5,251 )     (3,127 )
  Retained earnings (accumulated deficit)     11,293       (1,057 )
                   
    Total stockholders' equity     109,396       107,461  
                 
    $ 132,311     $ 130,976  
                 
                 
   
CASCADE MICROTECH, INC.  
AND SUBSIDIARIES  
   
Reconciliation of GAAP to Non-GAAP Financial Measures  
(in thousands, except per share amounts)  
(unaudited)  
                       
                       
    Three Months Ended          
    December 31,   September 30,   December 31,   Year Ended December 31,  
Non-GAAP Net Income   2015   2015   2014   2015   2014  
GAAP net income   $ 4,161   $ 3,219   $ 4,303   $ 12,350   $ 9,930  
                                 
Adjustments to net income:                                
  Restructuring     -     -     1,178     262     1,236  
  Acquisition and acquisition related     -     -     -     -     (557 )
  Amortization of intangibles     582     593     694     2,458     3,011  
  Income tax effect of non-GAAP adjustments     (195 )   (196 )   (509 )   (894 )   (1,170 )
  Discrete tax items     -     (204 )   (1,246 )   (358 )   (1,246 )
Non-GAAP net income   $ 4,548   $ 3,412   $ 4,420   $ 13,818   $ 11,204  
                                 
GAAP net income per diluted share   $ 0.25   $ 0.19   $ 0.25   $ 0.73   $ 0.59  
Non-GAAP net income per diluted share   $ 0.28   $ 0.20   $ 0.26   $ 0.81   $ 0.67  
                                 
Shares used in diluted share calculations     16,517     17,112     16,955     16,957     16,828  
                                 
                                 
    Three Months Ended          
    December 31,   September 30,   December 31,   Year Ended December 31,  
EBITDAS and Adjusted EBITDAS   2015   2015   2014   2015   2014  
GAAP Income from operations   $ 6,540   $ 4,512   $ 4,140   $ 17,891   $ 13,284  
                                 
Adjustments:                                
  Depreciation     852     785     883     3,109     3,335  
  Amortization of intangibles     582     593     694     2,458     3,011  
  Stock-based compensation     816     805     564     2,825     2,482  
EBITDAS     8,790     6,695     6,281     26,283     22,112  
                                 
Adjustments:                                
  Restructuring     -     -     1,178     262     1,236  
  Acquisition and acquisition related     -     -     -     -     (557 )
Adjusted EBITDAS   $ 8,790   $ 6,695   $ 7,459   $ 26,545   $ 22,791  
                                 
                                 
    Three Months Ending March 31, 2016          
    Low Range Guidance       High Range Guidance          
Forward-looking non-GAAP net income                                
GAAP net income   $ 1,300         $ 2,300              
Adjustments:                                
  Amortization of intangibles     582           582              
  Income tax effect of non-GAAP adjustments     (186 )         (186 )            
Non-GAAP net income   $ 1,696         $ 2,696              
                                 
GAAP net income per diluted share   $ 0.08         $ 0.14              
Non-GAAP net income per diluted share   $ 0.10         $ 0.16              
                                 
Shares used in diluted share calculations     16,700           16,700              
                                 
                                 

Forward-Looking Statements

The statements in this release regarding attainment of our success model, our continued financial improvement, our expectations relating to investment in new product development and positioning for continued success in 2016 and statements under "Financial Outlook" regarding projected revenue, GAAP earnings per share, and non-GAAP earnings per share and assumptions supporting those projections, and other statements identified by terminology such as "will," "should," "expects," "estimates," "predicts," and "continue" or other derivations of these or other comparable terms are "forward-looking" statements within the meaning of the Securities Litigation Reform act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business based in part on assumptions made by management. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including: changes in demand for the Company's products; changes in product mix; potential delays and other factors affecting the timing of new product introductions; the timing of shipments and customer orders; constraints on supplies of components; excess or shortage of production capacity; potential failure of expected market opportunities to materialize; changes in foreign exchange rates; our ability or delay in integrating acquired businesses; and other risks discussed from time to time in the Company's Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2014. In addition, such statements could be affected by general industry and market conditions and growth rates and general domestic and international economic conditions. Such forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release.

Non-GAAP Financial Measures

In addition to disclosing financial results calculated in accordance with U.S. generally accepted accounting principles (GAAP), the Company's earnings release contains Non-GAAP financial measures, which are defined below and reconciled to GAAP financial measures in a table later in this release:

  • Non-GAAP net income is defined as GAAP net income before certain items (adjustments) such as restructuring, facility move and project costs, acquisition-related expenses, the amortization of intangibles and discrete tax items that we believe are either not representative of our ongoing operating performance or effect the comparability of results over time. Non-GAAP net income should not be construed as a substitute for net income as defined by GAAP. However, we regard non-GAAP net income as a complement to GAAP net income in assessing our financial performance over time and in the future. 
  • Adjusted EBITDAS is defined as income from continuing operations before depreciation and amortization and stock-based compensation and certain other items (adjustments) such as restructuring, facility move and project costs, and acquisition-related expenses that we believe are not representative of our ongoing operating performance. Adjusted EBITDAS should not be construed as a substitute for net income from continuing operations or net cash provided by (used in) operating activities (all as determined in accordance with GAAP) for the purpose of analyzing our operating performance, financial position and cash flows, as adjusted EBITDAS is not defined by GAAP. However, we regard adjusted EBITDAS as a complement to net income from continuing operations and other GAAP financial performance measures, by including an indirect measure of operating cash flow.

About Cascade Microtech, Inc.

Cascade Microtech, Inc. ( NASDAQ : CSCD ) is a worldwide leader in precision contact, electrical measurement and test of integrated circuits (ICs), optical devices and other small structures. For technology businesses and scientific institutions that need to evaluate small structures, Cascade Microtech delivers access to electrical data from wafers, ICs, IC packages, circuit boards and modules, MEMS, 3D TSV, LED devices and more. Cascade Microtech's leading-edge stations, probes, probe cards, advanced thermal subsystems and integrated systems deliver precision accuracy and superior performance both in the lab and during production manufacturing of high-speed and high-density semiconductor chips. For more information, visit www.cascademicrotech.com .

FOR MORE INFORMATION, CONTACT: Jeff A. Killian Cascade Microtech, Inc. (503) 601-1280

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 199

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 150

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading

Top 5 Most Recently Viewed Articles

Japan's Economic Outlook Dims as Export Weakness Persists

Updated Category News Views 189

Japan's Revised Economic Growth Forecast Recently, Japan's government announced a downward revision of its GDP growth forecast for the current fiscal year. This adjustment is significant as it reflects the ongoing struggles within the economy, particularly in light of weaker export performance that is hindering a fragile recovery. Details on the Growth Projection The...

Continue Reading
The Importance of Employee Recognition in the Workplace

Updated Category News Views 254

The Importance of Employee Recognition in the Workplace Gratitude is a key theme during Thanksgiving, but in the workplace, recognition for employee contributions plays an equally significant role throughout the year. As companies strive to enhance their workplace culture, the value of recognizing employees cannot be overstated. Understanding Employer Perspectives A...

Continue Reading
Class Action Alert for Shareholders of Orthofix Medical

Updated Category News Views 196

Class Action Lawsuit Overview In the current landscape of securities litigation, investors in Orthofix Medical, Inc. have a critical opportunity to engage with a class action lawsuit that addresses significant issues of corporate governance and transparency. This legal action has arisen following severe corporate management changes that have caused share price...

Continue Reading
Understanding Recent Trends in Lowe's Short Interest

Updated Category News Views 107

Understanding Lowe's Companies' Short Interest Lowe's Companies (NYSE: LOW) has seen its short percent of float decrease by 12.78% since the last report. Currently, there are approximately 6.55 million shares sold short, which constitutes 1.16% of all shares available for trading. Given the current trading volume, it would take traders about 2.91 days to cover their short...

Continue Reading
YD Bio Limited and EG Biomed Enhance Clinical Testing with CAP Accreditation

Updated Category News Views 151

Transformative Advancements in Clinical Testing by YD Bio Limited YD Bio Limited, a pioneering biotechnology company known for its advancements in DNA methylation-based cancer detection, recently celebrated a significant milestone through its collaboration with EG Biomed US Inc. This partnership has propelled forward the capabilities of clinical testing, particularly in...

Continue Reading